english.prescrire.org > Spotlight > 100 most recent > Tebentafusp (Kimmtrak°) in metastatic uveal melanoma


Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Tebentafusp (Kimmtrak°) in metastatic uveal melanoma

 Marketing Authorisations   Tebentafusp, a fusion protein consisting of a T cell receptor fused to an anti-CD3 antibody fragment, has been authorised in the European Union for the treatment of metastatic or inoperable uveal melanoma, in HLA-A*02:01-positive patients. About half of the population of western Europe are HLA-A*02:01-positive. Does tebentafusp extend survival in this situation? And what are its adverse effects?
Full article (2 pages) available for download by subscribers

©Prescrire 1 November 2023

Source: "Tebentafusp (Kimmtrak°) in metastatic uveal melanoma. Median survival extended by a few months, according to fragile data" Prescrire Int 2023; 32 (253): 257-259. Subscribers only.

Enjoy full access to Prescrire International, and support independent information